marketcaparena
Search

    ANIP

    ANI PHARMACEUTICALS INC

    Company overview

    Market capitalization
    —
    Employees
    970
    Latest publication
    2026-09-29
    About ANI PHARMACEUTICALS INC

    ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue266,044,000USD237,462,000USD247,060,000USD227,813,000USD211,371,000USD197,122,000USD190,574,000USD148,332,000USD
    Cost Of Revenue100,158,000USD114,501,000USD9,500,000USD116,021,000USD74,615,000USD73,037,000USD80,280,000USD63,075,000USD
    Gross Profit165,886,000USD122,961,000USD237,560,000USD111,792,000USD136,756,000USD124,085,000USD110,294,000USD85,257,000USD
    Research Development14,747,000USD10,600,000USD12,261,000USD12,304,000USD16,535,000USD10,564,000USD16,646,000USD10,128,000USD
    Selling General Administrative91,661,000USD73,655,000USD76,528,000USD76,656,000USD81,771,000USD76,528,000USD69,719,000USD79,075,000USD
    Total Operating Expenses125,426,000USD84,255,000USD189,385,000USD88,960,000USD122,864,000USD97,891,000USD114,672,000USD105,776,000USD
    Operating Income40,460,000USD38,706,000USD48,175,000USD22,832,000USD13,892,000USD26,194,000USD-4,378,000USD-20,519,000USD
    Total Other Income Expense Net-3,363,000USD1,515,000USD-16,696,000USD10,968,000USD-3,367,000USD-6,207,000USD-9,384,000USD-10,979,000USD
    Depreciation And Amortization19,640,000USD20,919,000USD22,613,000USD22,632,000USD23,281,000USD22,891,000USD22,600,000USD15,748,000USD
    Income Before Tax37,097,000USD40,221,000USD31,479,000USD33,800,000USD10,525,000USD19,987,000USD-13,762,000USD-31,498,000USD
    Income Tax Expense12,386,000USD10,729,000USD3,989,000USD7,183,000USD1,976,000USD4,306,000USD-3,486,000USD-7,332,000USD
    Net Income24,711,000USD29,492,000USD27,490,000USD24,134,000USD8,549,000USD15,681,000USD-10,276,000USD-24,166,000USD
    Interest Expense—3,769,000USD22,839,999USD4,727,000USD8,221,999USD8,107,000USD6,015,000USD2,331,000USD
    Net Interest Income—-3,769,000USD-4,411,000USD-4,727,000USD-5,438,000USD-5,484,000USD-6,015,000USD-2,331,000USD
    Tax Provision—10,729,000USD3,989,000USD7,183,000USD1,976,000USD4,306,000USD-3,486,000USD-7,332,000USD
    Net Income From Continuing Ops—29,492,000USD27,490,000USD26,617,000USD8,549,000USD15,681,000USD-10,276,000USD-24,166,000USD
    Ebit—38,706,000USD54,318,999USD38,527,000USD15,963,000USD25,471,000USD-7,747,000USD-29,167,000USD
    Ebitda—59,625,000USD76,931,999USD61,159,000USD39,244,000USD48,362,000USD14,853,000USD-13,419,000USD
    Reconciled Depreciation—20,919,000USD22,613,000USD22,632,000USD23,281,000USD22,891,000USD22,600,000USD15,748,000USD
    Unclassified Operating Expenses——100,596,000USD—24,558,000USD10,799,000USD28,307,000USD16,573,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue883,366,000USD614,376,000USD486,816,000USD316,385,000USD216,136,000USD208,475,000USD206,547,000USD201,576,000USD
    Cost Of Revenue432,727,000USD250,210,000USD181,513,000USD138,785,000USD100,610,000USD87,157,000USD63,154,000USD73,024,000USD
    Gross Profit450,639,000USD364,166,000USD305,303,000USD177,600,000USD115,526,000USD121,318,000USD143,393,000USD128,552,000USD
    Research Development51,664,000USD44,581,000USD34,286,000USD22,318,000USD11,369,000USD16,001,000USD19,806,000USD15,388,000USD
    Selling General Administrative317,745,000USD249,636,000USD150,423,000USD127,802,000USD84,294,000USD64,986,000USD55,843,000USD44,063,000USD
    Total Operating Expenses369,409,000USD363,582,000USD258,332,000USD212,883,000USD155,319,000USD137,334,000USD127,042,000USD93,193,000USD
    Operating Income81,230,000USD584,000USD46,971,000USD-35,283,000USD-39,793,000USD-16,016,000USD16,351,000USD35,359,000USD
    Interest Expense20,060,000USD17,602,000USD26,940,000USD28,052,000USD11,922,000USD9,452,000USD12,966,000USD14,758,000USD
    Net Interest Income-20,060,000USD-17,602,000USD-28,700,000USD-28,052,000USD-11,922,000USD-9,452,000USD-12,966,000USD-14,758,000USD
    Income Before Tax95,791,000USD-22,212,000USD19,872,000USD-62,665,000USD-56,058,000USD-25,962,000USD3,157,000USD20,051,000USD
    Income Tax Expense17,454,000USD-3,690,000USD1,093,000USD-14,769,000USD-13,455,000USD-3,414,000USD-2,937,000USD4,557,000USD
    Tax Provision17,454,000USD-3,690,000USD-184,000USD-14,769,000USD-13,455,000USD-3,414,000USD-2,937,000USD4,557,000USD
    Net Income78,337,000USD-18,522,000USD18,779,000USD-47,896,000USD-42,603,000USD-22,548,000USD6,094,000USD15,494,000USD
    Net Income From Continuing Ops78,337,000USD-18,522,000USD13,381,000USD-47,896,000USD-42,603,000USD-22,548,000USD6,094,000USD15,494,000USD
    Ebit115,851,000USD-4,610,000USD46,812,000USD-34,613,000USD-44,136,000USD-16,510,000USD16,123,000USD35,359,000USD
    Ebitda207,268,000USD63,121,000USD106,603,000USD25,040,000USD3,116,000USD28,128,000USD60,735,000USD69,101,000USD
    Depreciation And Amortization91,417,000USD67,731,000USD59,791,000USD59,653,000USD47,252,000USD44,638,000USD44,612,000USD33,742,000USD
    Reconciled Depreciation91,417,000USD67,731,000USD60,169,000USD56,972,000USD47,252,000USD44,638,000USD44,612,000USD33,742,000USD
    Total Other Income Expense Net14,561,000USD-22,796,000USD-27,099,000USD-27,382,000USD-16,265,000USD-9,946,000USD-13,194,000USD-15,308,000USD
    Unclassified Operating Expenses—69,365,000USD73,623,000USD62,763,000USD59,656,000USD56,347,000USD51,393,000USD33,742,000USD
    Non Operating Income Net Other———670,000USD-4,343,000USD-494,000USD-228,000USD-550,000USD
    Net Income Applicable To Common Shares———-49,521,000USD-42,793,000USD-22,548,000USD6,094,000USD15,494,000USD
    Interest Income——————12,966,000USD14,758,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets1,494,112,000USD1,421,970,000USD1,440,377,000USD1,408,152,000USD1,343,001,000USD1,292,428,000USD1,283,697,000USD1,287,377,000USD
    Cash And Equivalents360,212,000USD———————
    Total Current Assets825,433,000USD747,084,000USD753,117,000USD698,402,000USD602,630,000USD536,290,000USD527,684,000USD521,297,000USD
    Other Non Current Assets11,624,000USD———————
    Total Liabilities896,900,000USD———————
    Total Current Liabilities283,655,000USD239,510,000USD278,112,000USD270,555,000USD236,835,000USD201,815,000USD193,680,000USD189,933,000USD
    Other Current Liabilities16,575,000USD———————
    Other Non Current Liabilities15,535,000USD———————
    Total Stockholder Equity597,212,000USD562,300,000USD540,724,000USD505,817,000USD461,607,000USD443,470,000USD428,530,000USD430,798,000USD
    Total Equity Including Noncontrolling Interest597,212,000USD———————
    Short Long Term Debt21,329,000USD19,298,000USD17,268,000USD15,241,000USD13,216,000USD11,193,000USD9,172,000USD7,152,000USD
    Long Term Debt280,155,000USD594,462,000USD599,767,000USD605,069,000USD608,346,000USD611,629,000USD614,920,000USD618,211,000USD
    Net Receivables274,469,000USD255,432,000USD281,082,000USD252,617,000USD225,654,000USD220,334,000USD221,726,000USD196,361,000USD
    Inventory143,149,000USD143,468,000USD143,067,000USD146,475,000USD138,315,000USD137,408,000USD136,782,000USD148,042,000USD
    Property Plant Equipment Net73,223,000USD67,115,000USD62,476,000USD63,560,000USD59,247,000USD58,179,000USD56,863,000USD56,704,000USD
    Goodwill62,480,000USD———————
    Intangible Assets449,857,000USD467,161,000USD479,526,000USD499,817,000USD520,320,000USD538,495,000USD541,834,000USD569,825,000USD
    Accounts Payable73,830,000USD69,694,000USD62,583,000USD69,795,000USD54,569,000USD53,058,000USD45,656,000USD60,890,000USD
    Common Stock3,000USD3,000USD3,000USD3,000USD2,000USD2,000USD2,000USD2,000USD
    Retained Earnings31,104,000USD6,393,000USD-23,099,000USD-50,589,000USD-76,862,000USD-85,004,000USD-100,279,000USD-89,597,000USD
    Accumulated Other Comprehensive Income-327,000USD479,000USD1,033,000USD2,811,000USD3,312,000USD3,610,000USD5,344,000USD5,366,000USD
    Other Current Assets—37,008,000USD43,383,000USD36,700,000USD15,146,000USD23,360,000USD18,008,000USD23,614,000USD
    Total Liab—859,670,000USD899,653,000USD902,335,000USD881,394,000USD848,958,000USD855,167,000USD856,579,000USD
    Other Current Liab—145,221,000USD187,234,000USD176,265,000USD165,756,000USD123,376,000USD132,103,000USD121,891,000USD
    Capital Stock—3,000USD3,000USD3,000USD24,852,000USD24,852,000USD24,852,000USD24,852,000USD
    Good Will—62,480,000USD62,480,000USD62,480,000USD60,533,000USD60,662,000USD59,990,000USD60,426,000USD
    Cash—311,176,000USD285,585,000USD262,610,000USD217,797,000USD149,802,000USD144,861,000USD144,982,000USD
    Cash And Short Term Investments—311,176,000USD285,585,000USD262,610,000USD223,515,000USD155,188,000USD151,168,000USD153,280,000USD
    Net Debt—16,588,000USD39,610,000USD60,023,000USD403,765,000USD473,020,000USD479,231,000USD480,381,000USD
    Short Term Debt—19,298,000USD17,268,000USD15,241,000USD13,216,000USD11,193,000USD9,172,000USD7,152,000USD
    Short Long Term Debt Total—327,764,000USD325,195,000USD322,633,000USD621,562,000USD622,822,000USD624,092,000USD625,363,000USD
    Short Term Investments—14,885,000USD9,131,000USD8,859,000USD5,718,000USD5,386,000USD6,307,000USD8,298,000USD
    Common Stock Shares Outstanding—21,544,000shares21,228,000shares21,093,000shares20,308,000shares20,046,000shares19,445,000shares19,404,000shares
    Non Current Assets Total—674,886,000USD687,260,000USD709,750,000USD740,371,000USD756,138,000USD756,013,000USD766,080,000USD
    Non Current Liabilities Total—620,160,000USD621,541,000USD631,780,000USD644,559,000USD647,143,000USD661,487,000USD666,646,000USD
    Non Current Liabilities Other—25,698,000USD21,774,000USD22,649,000USD24,785,000USD24,446,000USD25,606,000USD27,119,000USD
    Non Currrent Assets Other—11,575,000USD13,706,000USD12,497,000USD8,246,000USD10,313,000USD12,220,000USD11,464,000USD
    Net Working Capital—507,574,000USD475,005,000USD427,847,000USD365,795,000USD334,475,000USD334,004,000USD331,364,000USD
    Unclassified Current Assets—-14,885,000USD-9,131,000USD-8,859,000USD————
    Unclassified Non Current Assets—66,555,000USD69,072,000USD71,396,000USD92,025,000USD88,489,000USD85,106,000USD67,661,000USD
    Unclassified Current Liabilities—-14,001,000USD-6,241,000USD-5,987,000USD-9,922,000USD2,995,000USD-2,423,000USD-13,256,000USD
    Unclassified Equity—555,422,000USD562,784,000USD553,589,000USD510,303,000USD500,010,000USD498,611,000USD490,175,000USD
    Property Plant Equipment Gross——115,166,000USD———101,743,000USD—
    Unclassified Non Current Liabilities————11,428,000USD11,068,000USD20,961,000USD21,316,000USD
    Current Deferred Revenue———————6,104,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets1,440,377,000USD1,283,697,000USD904,422,000USD760,087,000USD771,598,000USD461,190,000USD456,789,000USD430,604,000USD
    Intangible Assets479,526,000USD541,834,000USD209,009,000USD251,635,000USD294,122,000USD188,511,000USD180,388,000USD201,604,000USD
    Other Current Assets43,383,000USD18,008,000USD25,420,000USD25,240,000USD11,256,000USD5,861,000USD5,071,000USD4,524,000USD
    Total Liab899,653,000USD855,167,000USD446,823,000USD421,547,000USD412,858,000USD265,490,000USD243,998,000USD233,341,000USD
    Total Stockholder Equity540,724,000USD428,530,000USD457,599,000USD338,540,000USD358,740,000USD195,700,000USD212,791,000USD197,263,000USD
    Other Current Liab187,234,000USD132,103,000USD99,780,000USD69,284,000USD59,966,000USD50,075,000USD36,678,000USD35,213,000USD
    Common Stock3,000USD2,000USD2,000USD1,000USD1,000USD1,000USD1,000USD1,000USD
    Capital Stock3,000USD24,852,000USD24,852,000USD24,851,000USD24,851,000USD1,000USD1,000USD1,000USD
    Retained Earnings-23,099,000USD-100,279,000USD-80,132,000USD-97,286,000USD-47,765,000USD-4,972,000USD17,584,000USD11,488,000USD
    Good Will62,480,000USD59,990,000USD28,221,000USD28,221,000USD27,888,000USD3,580,000USD3,580,000USD3,580,000USD
    Cash285,585,000USD144,861,000USD221,121,000USD48,228,000USD100,300,000USD7,864,000USD62,332,000USD43,008,000USD
    Cash And Short Term Investments285,585,000USD151,168,000USD221,121,000USD48,228,000USD100,300,000USD7,864,000USD62,332,000USD43,008,000USD
    Total Current Assets753,117,000USD527,684,000USD519,816,000USD344,261,000USD321,775,000USD170,321,000USD187,695,000USD152,877,000USD
    Total Current Liabilities278,112,000USD193,680,000USD145,477,000USD99,439,000USD87,537,000USD78,565,000USD61,676,000USD165,549,000USD
    Net Debt39,610,000USD479,231,000USD64,548,000USD238,291,000USD187,070,000USD177,822,000USD123,417,000USD140,007,000USD
    Short Term Debt17,268,000USD9,172,000USD850,000USD850,000USD850,000USD13,243,000USD9,941,000USD115,719,000USD
    Short Long Term Debt17,268,000USD9,172,000USD850,000USD850,000USD850,000USD13,243,000USD9,941,000USD115,719,000USD
    Short Long Term Debt Total325,195,000USD624,092,000USD285,669,000USD286,519,000USD287,370,000USD185,686,000USD185,749,000USD183,015,000USD
    Long Term Debt599,767,000USD614,920,000USD284,819,000USD285,669,000USD286,520,000USD172,443,000USD175,808,000USD67,296,000USD
    Short Term Investments9,131,000USD6,307,000USD0USD—————
    Net Receivables281,082,000USD221,726,000USD162,079,000USD165,438,000USD128,526,000USD95,793,000USD72,129,000USD64,842,000USD
    Inventory143,067,000USD136,782,000USD111,196,000USD105,355,000USD81,693,000USD60,803,000USD48,163,000USD40,503,000USD
    Accounts Payable62,583,000USD45,656,000USD36,683,000USD29,305,000USD22,967,000USD11,261,000USD14,606,000USD8,884,000USD
    Property Plant Equipment Net62,476,000USD56,863,000USD44,593,000USD43,246,000USD52,671,000USD41,269,000USD40,551,000USD38,090,000USD
    Property Plant Equipment Gross115,166,000USD101,743,000USD77,528,000USD75,958,000USD75,627,000USD41,269,000USD40,551,000USD38,090,000USD
    Accumulated Other Comprehensive Income1,033,000USD5,344,000USD8,857,000USD12,168,000USD-3,055,000USD-11,437,000USD-4,871,000USD-379,000USD
    Common Stock Shares Outstanding21,228,000shares19,318,000shares18,194,000shares16,260,000shares12,596,000shares11,964,000shares12,040,000shares11,772,000shares
    Non Current Assets Total687,260,000USD756,013,000USD384,606,000USD415,826,000USD449,823,000USD290,869,000USD269,094,000USD277,727,000USD
    Non Current Liabilities Total621,541,000USD661,487,000USD301,346,000USD322,108,000USD325,321,000USD186,925,000USD182,322,000USD67,792,000USD
    Non Current Liabilities Other21,774,000USD25,606,000USD16,527,000USD36,439,000USD31,000,000USD—6,514,000USD496,000USD
    Non Currrent Assets Other13,706,000USD12,220,000USD5,872,000USD11,361,000USD2,205,000USD802,000USD6,249,000USD1,468,000USD
    Net Working Capital475,005,000USD334,004,000USD374,339,000USD244,822,000USD234,238,000USD91,756,000USD126,019,000USD-12,672,000USD
    Unclassified Current Assets-9,131,000USD———————
    Unclassified Non Current Assets69,072,000USD85,106,000USD96,911,000USD-11,361,000USD——-6,249,000USD—
    Unclassified Current Liabilities-6,241,000USD-2,423,000USD-25,175,000USD—2,817,000USD-9,337,000USD-9,941,000USD-110,697,000USD
    Unclassified Equity562,784,000USD498,611,000USD504,020,000USD398,806,000USD384,708,000USD212,107,000USD200,799,000USD186,811,000USD
    Unclassified Non Current Liabilities—20,961,000USD—-35,658,000USD-24,015,000USD13,781,000USD—-1,964,000USD
    Current Deferred Revenue——32,489,000USD—87,000USD80,000USD451,000USD711,000USD
    Deferred Long Term Liab———600,000USD800,000USD500,000USD800,000USD1,468,000USD
    Other Liab———35,058,000USD31,016,000USD201,000USD7,000USD496,000USD
    Other Assets———92,724,000USD75,142,000USD57,509,000USD44,575,000USD34,453,000USD
    Accumulated Depreciation———-32,712,000USD-22,956,000USD———
    Net Tangible Assets———58,684,000USD36,730,000USD3,609,000USD28,823,000USD-7,921,000USD
    Treasury Stock——————-723,000USD-659,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income27,429,000USD27,490,000USD26,617,000USD8,549,000USD15,681,000USD-10,276,000USD-24,166,000USD-2,287,000USD
    Depreciation20,919,000USD22,613,000USD22,632,000USD23,281,000USD22,891,000USD22,600,000USD15,748,000USD14,697,000USD
    Stock Based Compensation10,191,000USD9,768,000USD9,691,000USD9,602,000USD8,868,000USD7,061,000USD7,484,000USD7,864,000USD
    Other Non Cash Items7,130,000USD-5,007,000USD-15,850,000USD1,680,000USD-10,395,000USD18,788,000USD10,668,000USD3,544,000USD
    Change To Account Receivables25,528,000USD-27,856,000USD-26,965,000USD-5,491,000USD1,782,000USD-25,513,000USD8,438,000USD6,327,000USD
    Change To Inventory-437,000USD3,732,000USD-8,160,000USD-908,000USD-625,000USD-675,000USD-6,360,000USD-11,611,000USD
    Change In Working Capital382,000USD-26,853,000USD-17,835,000USD36,236,000USD1,329,000USD-4,783,000USD8,327,999USD-4,505,000USD
    Total Cash From Operating Activities58,375,000USD30,367,000USD44,055,000USD75,812,000USD34,991,000USD15,860,000USD12,474,000USD17,414,000USD
    Capital Expenditures-6,074,000USD-23,860,000USD-6,163,000USD-6,909,000USD-19,846,000USD-2,480,000USD-4,812,000USD-4,449,000USD
    Free Cash Flow52,301,000USD6,507,000USD37,892,000USD68,903,000USD15,145,000USD13,380,000USD7,662,000USD12,965,000USD
    Total Cashflows From Investing Activities-11,324,000USD-1,403,000USD-6,163,000USD-6,909,000USD-19,846,000USD-10,681,000USD-398,522,000USD-4,449,000USD
    Net Borrowings-4,063,000USD-4,063,000USD-2,031,000USD-2,031,000USD-2,031,000USD-2,031,000USD348,750,000USD—
    Total Cash From Financing Activities-21,616,000USD-4,636,000USD6,345,000USD-1,747,000USD-9,906,000USD-4,907,000USD291,030,000USD-1,452,000USD
    Dividends Paid0USD0USD-344,000USD-407,000USD-406,000USD-406,000USD-406,000USD-407,000USD
    Sale Purchase Of Stock-19,755,000USD-611,000USD-1,044,000USD-551,000USD-10,003,000USD-318,000USD-680,000USD-1,300,000USD
    Change In Cash25,591,000USD22,975,000USD44,813,000USD67,997,000USD4,942,000USD-123,000USD-95,093,000USD11,513,000USD
    Begin Period Cash Flow285,621,000USD262,646,000USD217,833,000USD149,836,000USD144,894,000USD145,017,000USD240,110,000USD228,597,000USD
    End Period Cash Flow311,212,000USD285,621,000USD262,646,000USD217,833,000USD149,836,000USD144,894,000USD145,017,000USD240,110,000USD
    Other Cashflows From Investing Activities-11,324,000USD7,980,000USD-60,000USD-2,895,000USD-17,372,000USD-86,000USD-631,000USD—
    Other Cashflows From Financing Activities-21,616,000USD-4,636,000USD8,720,000USD691,000USD2,534,000USD-42,450,000USD586,491,000USD-8,956,000USD
    Unclassified Operating Cash Flow-7,676,000USD2,356,000USD18,800,000USD-3,536,000USD-3,383,000USD-17,530,000USD-5,587,999USD-1,899,000USD
    Unclassified Investing Cash Flow6,074,000USD14,477,000USD6,223,000USD9,804,000USD37,218,000USD2,566,000USD5,443,000USD4,449,000USD
    Unclassified Financing Cash Flow23,818,000USD4,674,000USD1,044,000USD——40,298,000USD-643,125,000USD9,211,000USD
    Investments——-6,163,000USD-6,909,000USD-19,846,000USD-10,681,000USD-398,522,000USD-4,449,000USD
    Issuance Of Capital Stock—————0USD0USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income78,337,000USD-18,522,000USD18,779,000USD-47,896,000USD-42,603,000USD-22,548,000USD6,094,000USD15,494,000USD
    Depreciation91,417,000USD67,731,000USD59,791,000USD59,653,000USD47,252,000USD44,638,000USD44,612,000USD33,742,000USD
    Stock Based Compensation37,929,000USD29,344,000USD20,652,000USD14,599,000USD10,489,000USD12,936,000USD9,217,000USD6,782,000USD
    Other Non Cash Items-29,572,000USD18,562,000USD6,617,000USD8,994,000USD5,022,000USD6,074,000USD9,423,000USD10,268,000USD
    Change To Account Receivables-58,530,000USD-21,087,000USD3,359,000USD-36,912,000USD-5,548,000USD-23,664,000USD-7,287,000USD-4,743,000USD
    Change To Inventory-5,961,000USD-21,287,000USD-5,841,000USD-23,626,000USD3,224,000USD-2,759,000USD-7,660,000USD-379,000USD
    Change In Working Capital-7,123,000USD-11,185,000USD24,860,000USD-51,300,000USD-84,000USD-12,628,000USD-14,581,000USD5,968,000USD
    Total Cash From Operating Activities185,225,000USD64,017,000USD118,959,000USD-31,203,000USD3,322,000USD15,267,000USD45,631,000USD67,074,000USD
    Capital Expenditures-13,835,000USD-16,953,000USD-18,511,000USD-16,455,000USD-23,638,000USD-68,322,000USD-27,549,000USD-10,912,000USD
    Free Cash Flow171,390,000USD47,064,000USD100,448,000USD-47,658,000USD-20,316,000USD-53,055,000USD18,082,000USD56,162,000USD
    Total Cashflows From Investing Activities-34,321,000USD-404,719,000USD-18,511,000USD-15,738,000USD-105,483,000USD-68,322,000USD-27,549,000USD-27,379,000USD
    Net Borrowings-10,156,000USD345,219,000USD-3,000,000USD-3,000,000USD99,022,000USD-534,000USD-121,457,000USD-28,938,000USD
    Total Cash From Financing Activities-9,944,000USD264,945,000USD67,439,000USD-5,126,000USD194,595,000USD-1,439,000USD1,250,000USD-27,816,000USD
    Dividends Paid-1,157,000USD-1,625,000USD-1,625,000USD-1,625,000USD-190,000USD-618,000USD-5,738,000USD-190,000USD
    Sale Purchase Of Stock-12,209,000USD-10,959,000USD-4,987,000USD-1,959,000USD-890,000USD-1,523,000USD-1,031,000USD-659,000USD
    Issuance Of Capital Stock0USD0USD80,555,000USD80,555,000USD100,000,000USD0USD——
    Change In Cash140,727,000USD-76,227,000USD167,887,000USD-52,067,000USD92,434,000USD-54,494,000USD19,332,000USD11,879,000USD
    Begin Period Cash Flow144,894,000USD221,121,000USD53,234,000USD105,301,000USD12,867,000USD67,361,000USD48,029,000USD36,150,000USD
    End Period Cash Flow285,621,000USD144,894,000USD221,121,000USD53,234,000USD105,301,000USD12,867,000USD67,361,000USD48,029,000USD
    Other Cashflows From Investing Activities-34,321,000USD12,797,000USD-9,643,000USD-6,862,000USD-102,926,000USD-62,187,000USD-20,914,000USD-5,169,000USD
    Other Cashflows From Financing Activities-26,000USD-67,690,000USD-3,504,000USD1,458,000USD331,685,000USD618,000USD-113,012,000USD-24,344,000USD
    Unclassified Operating Cash Flow14,237,000USD-21,913,000USD-11,740,000USD-15,253,000USD-16,754,000USD-13,205,000USD-9,134,000USD-5,180,000USD
    Unclassified Investing Cash Flow13,835,000USD4,156,000USD26,517,000USD23,317,000USD126,564,000USD130,509,000USD48,463,000USD16,081,000USD
    Unclassified Financing Cash Flow13,604,000USD—80,555,000USD—-235,032,000USD—242,488,000USD26,315,000USD
    Investments—-404,719,000USD-16,874,000USD-15,738,000USD-105,483,000USD-68,322,000USD-27,549,000USD-27,379,000USD
    Change To Liabilities———4,878,000USD2,593,000USD2,688,000USD-1,059,000USD5,942,000USD
    Cash And Cash Equivalents Changes———-52,067,000USD92,434,000USD-54,494,000USD19,332,000USD11,879,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30SegmentGenerics And Other100,656,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30SegmentRare Disease And Brands165,388,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31SegmentGenerics And Other109,220,000USD0001023024-26-000050
    Q1 2026Quarterly · 2026-03-31SegmentRare Disease And Brands128,242,000USD0001023024-26-000050
    Q4 2025Quarterly · 2025-12-31SegmentGenerics And Other103,492,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31SegmentRare Disease And Brands143,568,000USDLegacy provider
    FY 2025Yearly · 2025-12-31GeographyInternational30,923,000USD0001023024-26-000014
    FY 2025Yearly · 2025-12-31GeographyUnited States852,443,000USD0001023024-26-000014
    FY 2025Yearly · 2025-12-31SegmentGenerics And Other399,433,000USD0001023024-26-000014
    FY 2025Yearly · 2025-12-31SegmentRare Disease And Brands483,933,000USD0001023024-26-000014
    Q3 2025Quarterly · 2025-09-30SegmentGenerics And Other98,688,000USD0001023024-25-000108
    Q3 2025Quarterly · 2025-09-30SegmentRare Disease And Brands129,125,000USD0001023024-25-000108
    Q2 2025Quarterly · 2025-06-30SegmentGenerics And Other94,213,000USD0001023024-25-000082
    Q2 2025Quarterly · 2025-06-30SegmentRare Disease And Brands117,158,000USD0001023024-25-000082
    Q1 2025Quarterly · 2025-03-31SegmentGenerics And Other103,040,000USD0001023024-26-000050
    Q1 2025Quarterly · 2025-03-31SegmentRare Disease And Brands94,082,000USD0001023024-26-000050
    Q4 2024Quarterly · 2024-12-31SegmentGenerics And Other83,688,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31SegmentRare Disease And Brands106,886,000USDLegacy provider
    FY 2024Yearly · 2024-12-31GeographyInternational9,387,000USD0001023024-26-000014
    FY 2024Yearly · 2024-12-31GeographyUnited States604,989,000USD0001023024-26-000014
    FY 2024Yearly · 2024-12-31SegmentGenerics And Other320,034,000USD0001023024-26-000014
    FY 2024Yearly · 2024-12-31SegmentRare Disease And Brands294,342,000USD0001023024-26-000014
    Q3 2024Quarterly · 2024-09-30SegmentGenerics And Other82,711,000USD0001023024-25-000108
    Q3 2024Quarterly · 2024-09-30SegmentRare Disease And Brands65,621,000USD0001023024-25-000108
    Q3 2024Quarterly · 2024-09-30GeographyInternational1,216,000USD0001023024-24-000102
    Q3 2024Quarterly · 2024-09-30GeographyUnited States147,116,000USD0001023024-24-000102
    Q2 2024Quarterly · 2024-06-30GeographyCanada0USD0001023024-24-000085
    Q2 2024Quarterly · 2024-06-30GeographyUnited States138,040,000USD0001023024-24-000085
    Q1 2024Quarterly · 2024-03-31GeographyCanada0USD0001023024-24-000057
    Q1 2024Quarterly · 2024-03-31GeographyUnited States137,430,000USD0001023024-24-000057
    FY 2023Yearly · 2023-12-31GeographyInternational565,000USD0001023024-26-000014
    FY 2023Yearly · 2023-12-31GeographyUnited States486,251,000USD0001023024-26-000014
    FY 2023Yearly · 2023-12-31SegmentGenerics And Other289,314,000USD0001023024-26-000014
    FY 2023Yearly · 2023-12-31SegmentRare Disease And Brands197,502,000USD0001023024-26-000014
    Q4 2023Quarterly · 2023-12-31GeographyCanada0USDLegacy provider
    Q4 2023Quarterly · 2023-12-31GeographyUnited States131,654,000USDLegacy provider
    Q3 2023Quarterly · 2023-09-30GeographyInternational0USD0001023024-24-000102
    Q3 2023Quarterly · 2023-09-30GeographyUnited States131,829,000USD0001023024-24-000102
    Q2 2023Quarterly · 2023-06-30GeographyCanada0USD0001023024-24-000085
    Q2 2023Quarterly · 2023-06-30GeographyUnited States116,547,000USD0001023024-24-000085
    Q1 2023Quarterly · 2023-03-31GeographyCanada565,000USD0001023024-24-000057
    Q1 2023Quarterly · 2023-03-31GeographyUnited States106,221,000USD0001023024-24-000057
    FY 2022Yearly · 2022-12-31GeographyInternational3,958,000USD0001023024-25-000015
    FY 2022Yearly · 2022-12-31GeographyUnited States312,427,000USD0001023024-25-000015
    FY 2022Yearly · 2022-12-31SegmentGenerics And Other235,237,000USD0001023024-25-000015
    FY 2022Yearly · 2022-12-31SegmentRare Disease And Brands81,148,000USD0001023024-25-000015
    Q4 2022Quarterly · 2022-12-31GeographyCanada1,227,000USDLegacy provider
    Q4 2022Quarterly · 2022-12-31GeographyUnited States93,005,000USDLegacy provider
    FY 2021Yearly · 2021-12-31GeographyCanada4,243,000USD0001023024-24-000026
    FY 2021Yearly · 2021-12-31GeographyUnited States211,893,000USD0001023024-24-000026
    FY 2021Yearly · 2021-12-31SegmentGenerics Established Brands And Other216,136,000USD0001023024-24-000026
    FY 2021Yearly · 2021-12-31SegmentRare Disease0USD0001023024-24-000026
    FY 2020Yearly · 2020-12-31GeographyCanada5,594,000USD0001023024-23-000005
    FY 2020Yearly · 2020-12-31GeographyUnited States202,881,000USD0001023024-23-000005
    Q2 2020Quarterly · 2020-06-30ProductOther Revenues161,000USD0001558370-20-009520
    Q2 2020Quarterly · 2020-06-30ProductProduct Development Services885,000USD0001558370-20-009520
    Q2 2020Quarterly · 2020-06-30ProductRoyalties From Licensing Agreements491,000USD0001558370-20-009520
    Q2 2020Quarterly · 2020-06-30ProductSales Of Branded Pharmaceutical Products10,633,000USD0001558370-20-009520
    Q2 2020Quarterly · 2020-06-30ProductSales Of Contract Manufactured Products2,900,000USD0001558370-20-009520
    Q2 2020Quarterly · 2020-06-30ProductSales Of Generic Pharmaceutical Products33,400,000USD0001558370-20-009520
    Q1 2020Quarterly · 2020-03-31ProductOther Revenues281,000USD0001104659-20-057791
    Q1 2020Quarterly · 2020-03-31ProductProduct Development Services577,000USD0001104659-20-057791
    Q1 2020Quarterly · 2020-03-31ProductRoyalties From Licensing Agreements290,000USD0001104659-20-057791
    Q1 2020Quarterly · 2020-03-31ProductSales Of Branded Pharmaceutical Products9,157,000USD0001104659-20-057791
    Q1 2020Quarterly · 2020-03-31ProductSales Of Contract Manufactured Products1,974,000USD0001104659-20-057791
    Q1 2020Quarterly · 2020-03-31ProductSales Of Generic Pharmaceutical Products37,495,000USD0001104659-20-057791
    FY 2019Yearly · 2019-12-31GeographyCanada6,884,000USD0001023024-22-000004
    FY 2019Yearly · 2019-12-31GeographyUnited States199,663,000USD0001023024-22-000004
    Q4 2019Quarterly · 2019-12-31ProductOther Revenues50,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductProduct Development Services319,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductRoyalties From Licensing Agreements213,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductSales Of Branded Pharmaceutical Products15,623,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductSales Of Contract Manufactured Products2,639,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductSales Of Generic Pharmaceutical Products29,122,000USDLegacy provider
    FY 2019Yearly · 2019-12-31ProductOther Revenues980,000USD0001104659-20-025744
    FY 2019Yearly · 2019-12-31ProductProduct Development Services1,125,000USD0001104659-20-025744
    FY 2019Yearly · 2019-12-31ProductRoyalties From Licensing Agreements807,000USD0001104659-20-025744
    FY 2019Yearly · 2019-12-31ProductSales Of Branded Pharmaceutical Products63,767,000USD0001104659-20-025744
    FY 2019Yearly · 2019-12-31ProductSales Of Contract Manufactured Products11,139,000USD0001104659-20-025744
    FY 2019Yearly · 2019-12-31ProductSales Of Generic Pharmaceutical Products128,729,000USD0001104659-20-025744
    Q3 2019Quarterly · 2019-09-30ProductOther Revenues260,000USD0001104659-19-060283
    Q3 2019Quarterly · 2019-09-30ProductProduct Development Services75,000USD0001104659-19-060283
    Q3 2019Quarterly · 2019-09-30ProductRoyalties From Licensing Agreements268,000USD0001104659-19-060283
    Q3 2019Quarterly · 2019-09-30ProductSales Of Branded Pharmaceutical Products16,605,000USD0001104659-19-060283
    Q3 2019Quarterly · 2019-09-30ProductSales Of Contract Manufactured Products2,376,000USD0001104659-19-060283
    Q3 2019Quarterly · 2019-09-30ProductSales Of Generic Pharmaceutical Products31,753,000USD0001104659-19-060283
    Q2 2019Quarterly · 2019-06-30ProductOther Revenues259,000USD0001558370-20-009520
    Q2 2019Quarterly · 2019-06-30ProductProduct Development Services411,000USD0001558370-20-009520
    Q2 2019Quarterly · 2019-06-30ProductRoyalties From Licensing Agreements-251,000USD0001558370-20-009520
    Q2 2019Quarterly · 2019-06-30ProductSales Of Branded Pharmaceutical Products13,996,000USD0001558370-20-009520
    Q2 2019Quarterly · 2019-06-30ProductSales Of Contract Manufactured Products3,687,000USD0001558370-20-009520
    Q2 2019Quarterly · 2019-06-30ProductSales Of Generic Pharmaceutical Products36,255,000USD0001558370-20-009520
    Q1 2019Quarterly · 2019-03-31ProductOther Revenues411,000USD0001104659-20-057791
    Q1 2019Quarterly · 2019-03-31ProductProduct Development Services320,000USD0001104659-20-057791
    Q1 2019Quarterly · 2019-03-31ProductRoyalties From Licensing Agreements577,000USD0001104659-20-057791
    Q1 2019Quarterly · 2019-03-31ProductSales Of Branded Pharmaceutical Products17,543,000USD0001104659-20-057791
    Q1 2019Quarterly · 2019-03-31ProductSales Of Contract Manufactured Products2,437,000USD0001104659-20-057791
    Q1 2019Quarterly · 2019-03-31ProductSales Of Generic Pharmaceutical Products31,599,000USD0001104659-20-057791
    FY 2018Yearly · 2018-12-31GeographyCanada4,690,000USD0001023024-21-000007
    FY 2018Yearly · 2018-12-31GeographyUnited States196,886,000USD0001023024-21-000007

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.